Skip to main content

Table 3 Percentage of inhibition of Aβ42 aggregation by Cur or SLCP in comparison to untreated group, *p < 0.05, **p < 0.01, relative to untreated Aβ42

From: Preservation of dendritic spine morphology and postsynaptic signaling markers after treatment with solid lipid curcumin particles in the 5xFAD mouse model of Alzheimer’s amyloidosis

  6-E10 antibodies OC antibodies A11 antibody
Duration 24 h 48 h 24 h 48 h 8 h
Treatment Groups Aβ42+
Cur
Aβ42+
SLCP
Aβ42+
Cur
Aβ42+
SLCP
Aβ42+
Cur
Aβ42+
SLCP
Aβ42+
Cur
Aβ42+
SLCP
Aβ42+
Cur
Aβ42+
SLCP
1 μM 64.54 48.34* 26.25 51.68** 16.99 41.04** 18.95 37.11* 24.20 43.75*
100 nM 71.99 48.44** 31.21 58.69** 21.64 30.59 60.81 36.45* 7.63 48.37**
10 nM 63.96 59.76 18.38 65.70** 27.54 35.15 105.15 33.29* 17.59 53.68**
1 nM 65.05 55.82* 37.34 65.00** 23.07 38.70* − 73.09 56.82** 22.37 46.74*